ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc (FRX)

9,46
0,00
( 0,00% )
Mis à jour : 16:03:46

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

Dernier
9,46
Prix Achat
9,33
Prix Vente
9,55
Volume échangé
-
0,00 Fourchette du Jour 0,00
5,65 Plage de 52 semaines 15,20
Cap du marché
Clôture Veille
9,46
Ouverture
-
Dernière Transaction
Dernière heure de transaction
-
Volume financier
-
VWAP
-
Volume moyen (3 m)
2 139
Actions en circulation
27 027 000
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-15,93
Bénéfice par action (BPA)
-0,59
Chiffre d'affairess
21,25M
Bénéfice net
-16,05M

À propos de Fennec Pharmaceuticals Inc

Secteur
Biological Pds,ex Diagnstics
Industrie
Biological Pds,ex Diagnstics
Siège social
Ottawa, Ontario, Can
Fondé
-
Fennec Pharmaceuticals Inc est coté dans le secteur Biological Pds,ex Diagnstics de la Toronto Stock Exchange avec le ticker FRX. Le dernier cours de clôture d'Fennec Pharmaceuticals était de $9,46. Au cours de la dernière année, les actions de Fennec Pharmaceuticals ont été négociées dans une fourchette de prix de $ 5,65 à $ 15,20.

Fennec Pharmaceuticals compte actuellement 27 027 000 actions en circulation. La capitalisation boursière d'Fennec Pharmaceuticals est de $255,68 million. Fennec Pharmaceuticals a un ratio cours/bénéfice (ratio PE) de -15.93.

FRX Dernières nouvelles

Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany

~ PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to <18 Years of...

Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales

~ PEDMARQSI® (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children...

Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management

~ $13 Million Convertible Debt Repayment from Available Cash ~ ~ Elimination of Approximately $1.5 Million in Annual Interest Expense and Potential Equity Overhang of Approximately 1.6 Million...

Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the...

Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the...

Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic...

Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that...

Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company’s Next Stage of Growth

~ Pierre S. Sayad, PhD, M.S., Appointed Chief Medical Officer ~ ~ Terry Evans Appointed Chief Commercial Officer ~ ~ Christiana Cioffi, MBA, Appointed Chief Strategy Officer ~ RESEARCH TRIANGLE...

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that...

Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

~ Achieved Second Quarter 2024 Total Net Revenues of $7.3 Million ~ ~ Appointed Jeffrey S. Hackman as Chief Executive Officer (CEO) and Member of the Board of Directors ~ ~ Company Has...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.28-2.874743326499.749.749.022949.42832653CS
41.1613.97590361458.39.747.818449.2305553CS
123.7866.54929577465.689.745.6821398.50388766CS
261.2214.80582524278.249.745.6519447.49010636CS
52-3.94-29.402985074613.415.25.6515458.31838735CS
1562.8743.55083459796.5915.435.658879.48596719CS
260-0.19-1.96891191719.6515.434.9510469.19694535CS

FRX - Frequently Asked Questions (FAQ)

What is the current Fennec Pharmaceuticals share price?
The current share price of Fennec Pharmaceuticals is $ 9,46
How many Fennec Pharmaceuticals shares are in issue?
Fennec Pharmaceuticals has 27 027 000 shares in issue
What is the market cap of Fennec Pharmaceuticals?
The market capitalisation of Fennec Pharmaceuticals is CAD 255,68M
What is the 1 year trading range for Fennec Pharmaceuticals share price?
Fennec Pharmaceuticals has traded in the range of $ 5,65 to $ 15,20 during the past year
What is the PE ratio of Fennec Pharmaceuticals?
The price to earnings ratio of Fennec Pharmaceuticals is -15,93
What is the cash to sales ratio of Fennec Pharmaceuticals?
The cash to sales ratio of Fennec Pharmaceuticals is 12,03
What is the reporting currency for Fennec Pharmaceuticals?
Fennec Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Fennec Pharmaceuticals?
The latest annual turnover of Fennec Pharmaceuticals is USD 21,25M
What is the latest annual profit for Fennec Pharmaceuticals?
The latest annual profit of Fennec Pharmaceuticals is USD -16,05M
What is the registered address of Fennec Pharmaceuticals?
The registered address for Fennec Pharmaceuticals is C/O LABARGE WEINSTEIN LLP, 515 LEGGET DRIVE, SUITE 800, OTTAWA, ONTARIO, K2K 3G4
What is the Fennec Pharmaceuticals website address?
The website address for Fennec Pharmaceuticals is www.fennecpharma.com
Which industry sector does Fennec Pharmaceuticals operate in?
Fennec Pharmaceuticals operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
CVOCoveo Solutions Inc
$ 7,02
(15,27%)
246,77k
AEGAegis Brands Inc
$ 0,37
(12,12%)
4k
XAMXanadu Mines Ltd
$ 0,05
(11,11%)
13,12k
RVXResverlogix Corp
$ 0,05
(11,11%)
5k
PKIParkland Corporation
$ 37,15
(10,90%)
344,3k
VRTSVertiqal Studios Corporation
$ 0,015
(-25,00%)
300k
GMTNGold Mountain Mining Corp
$ 0,02
(-20,00%)
7,1k
EAGREast Side Games Group Inc
$ 0,405
(-14,74%)
895,55k
OGIOrganiGram Holdings Inc
$ 2,16
(-13,60%)
283,45k
AIIAlmonty Industries Inc
$ 1,90
(-10,38%)
400,38k
ENBEnbridge Inc
$ 64,06
(-0,14%)
7,02M
BMOBank of Montreal
$ 142,00
(-0,12%)
1,48M
CTSConverge Technology Solutions Corp
$ 5,40
(0,00%)
1,09M
EAGREast Side Games Group Inc
$ 0,405
(-14,74%)
895,55k
SHOPShopify Inc
$ 169,57
(-1,15%)
673,62k
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock